Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 2/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | INSR | P06213 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8138668 | 0.89 | NR1I2 (0.54) | NR1I2CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL8874130 | 0.84 | CYP3A4 (0.47) | NR1I2CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL14007038 | 0.84 | NR1I2 (0.45) | NR1I2CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL8130662 | 0.82 | NR1I2 (0.43) | NR1I2CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL8875424 | 0.81 | NR1I2 (0.47) | NR1I2CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL8875264 | 0.81 | NR1I2 (0.44) | NR1I2CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL8132275 | 0.78 | NR1I2 (0.41) | NR1I2CYP3A4CYP2D6KMT2AGAA | |
| SCHEMBL13623359 | 0.77 | NR1I2 (0.45) | NR1I2CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL13623363 | 0.76 | GAA (0.34) | KMT2AGAARAB9A | |
| SCHEMBL13623369 | 0.76 | NR1I2 (0.44) | NR1I2CYP3A4CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291990-A1 | OXADIAZOLYL-PHENOXYALKYLISOXAZOLES, COMPOSITIONS THEREOF AND METHODS FOR THEIR USE AS ANTI-PICORNAVIRAL AGENTS | RHODES GERALD | 2009-11-26 | — | — | US | disclosed |
| US-7585884-B2 | Oxadiazolyl-phenoxyalkylisoxazoles, compositions thereof and methods for their use as anti-picornaviral agents | VIROPHARMA INCORPORATED (US) | 2009-09-08 | — | — | US | disclosed |
| US-20080293783-A1 | OXADIAZOLYL-PHENOXYALKYLISOXAZOLES, COMPOSITIONS THEREOF AND METHODS FOR THEIR USE AS ANTI-PICORNAVIRAL AGENTS | VIROPHARMA INCORPORATED | 2008-11-27 | — | — | US | disclosed |
| US-7429606-B2 | Oxadiazolyl-phenoxyalkylisoxazoles, compositions thereof and methods for their use as anti-picornaviral agents | VIROPHARMA INCORPORATED (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293783-A1 | OXADIAZOLYL-PHENOXYALKYLISOXAZOLES, COMPOSITIONS THEREOF AND METHODS FOR THEIR USE AS ANTI-PICORNAVIRAL AGENTS | PLEC, CPSF7, CPSF1 | NR1I2 1884/4885CYP3A4 771/4885CYP2D6 2441/4885 |
| US-20090291990-A1 | OXADIAZOLYL-PHENOXYALKYLISOXAZOLES, COMPOSITIONS THEREOF AND METHODS FOR THEIR USE AS ANTI-PICORNAVIRAL AGENTS | PLEC, CPSF7, CPSF1 | NR1I2 1884/4885CYP3A4 771/4885CYP2D6 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.